These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 24248262)

  • 1. Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis.
    Jiao Y; Fryer JP; Lennon VA; McKeon A; Jenkins SM; Smith CY; Quek AM; Weinshenker BG; Wingerchuk DM; Shuster EA; Lucchinetti CF; Pittock SJ
    JAMA Neurol; 2014 Jan; 71(1):48-54. PubMed ID: 24248262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica.
    Jiao Y; Fryer JP; Lennon VA; Jenkins SM; Quek AM; Smith CY; McKeon A; Costanzi C; Iorio R; Weinshenker BG; Wingerchuk DM; Shuster EA; Lucchinetti CF; Pittock SJ
    Neurology; 2013 Oct; 81(14):1197-204. PubMed ID: 23997151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
    Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
    JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Seroprevalence and diagnostic value of aquaporin-4 antibody in patients with inflammatory central nervous system demyelinating diseases].
    Wu L; Yang Y; Huang DH; Wu WP
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Feb; 31(2):350-2. PubMed ID: 21354891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies.
    Kitley J; Leite MI; Küker W; Quaghebeur G; George J; Waters P; Woodhall M; Vincent A; Palace J
    JAMA Neurol; 2013 Nov; 70(11):1375-81. PubMed ID: 23999580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease.
    Magaña SM; Pittock SJ; Lennon VA; Keegan BM; Weinshenker BG; Lucchinetti CF
    Arch Neurol; 2009 Aug; 66(8):964-6. PubMed ID: 19667216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
    Mader S; Gredler V; Schanda K; Rostasy K; Dujmovic I; Pfaller K; Lutterotti A; Jarius S; Di Pauli F; Kuenz B; Ehling R; Hegen H; Deisenhammer F; Aboul-Enein F; Storch MK; Koson P; Drulovic J; Kristoferitsch W; Berger T; Reindl M
    J Neuroinflammation; 2011 Dec; 8():184. PubMed ID: 22204662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.
    Dubey D; Pittock SJ; Krecke KN; Morris PP; Sechi E; Zalewski NL; Weinshenker BG; Shosha E; Lucchinetti CF; Fryer JP; Lopez-Chiriboga AS; Chen JC; Jitprapaikulsan J; McKeon A; Gadoth A; Keegan BM; Tillema JM; Naddaf E; Patterson MC; Messacar K; Tyler KL; Flanagan EP
    JAMA Neurol; 2019 Mar; 76(3):301-309. PubMed ID: 30575890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells.
    Hinson SR; McKeon A; Fryer JP; Apiwattanakul M; Lennon VA; Pittock SJ
    Arch Neurol; 2009 Sep; 66(9):1164-7. PubMed ID: 19752309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is Asian type MS an MS phenotype, an NMO spectrum disorder, or a MOG-IgG related disease?
    Papais Alvarenga RM; Araújo ACRAE; Nascimento ACB; Araujo NEC; Meneguette NS; Neri VC; Papais Alvarenga M; Filho HA; Barros PO; Bento CA; Schmidt SL; Vasconcelos CCF; Alvarenga MP
    Mult Scler Relat Disord; 2020 Jul; 42():102082. PubMed ID: 32361664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct features between longitudinally extensive transverse myelitis presenting with and without anti-aquaporin 4 antibodies.
    Chang KH; Lyu RK; Chen CM; Wu YR; Chang HS; Huang CC; Kuo HC; Chu CC; Hsu WC; Ro LS
    Mult Scler; 2013 Mar; 19(3):299-307. PubMed ID: 22829325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis.
    Waters P; Jarius S; Littleton E; Leite MI; Jacob S; Gray B; Geraldes R; Vale T; Jacob A; Palace J; Maxwell S; Beeson D; Vincent A
    Arch Neurol; 2008 Jul; 65(7):913-9. PubMed ID: 18625857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese.
    Chan KH; Ramsden DB; Yu YL; Kwok KH; Chu AC; Ho PW; Kwan JS; Lee R; Lim E; Kung MH; Ho SL
    Eur J Neurol; 2009 Mar; 16(3):310-6. PubMed ID: 19138340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature.
    Jarius S; Wildemann B
    Brain Pathol; 2013 Nov; 23(6):661-83. PubMed ID: 24118483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays.
    McKeon A; Fryer JP; Apiwattanakul M; Lennon VA; Hinson SR; Kryzer TJ; Lucchinetti CF; Weinshenker BG; Wingerchuk DM; Shuster EA; Pittock SJ
    Arch Neurol; 2009 Sep; 66(9):1134-8. PubMed ID: 19752303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic value of aquaporin-4 antibody in patients of inflammatory demyelinating diseases in central nervous system].
    Yang Y; Wu WP; Huang DH; Wu L
    Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(43):3032-5. PubMed ID: 23328372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica.
    Mader S; Lutterotti A; Di Pauli F; Kuenz B; Schanda K; Aboul-Enein F; Khalil M; Storch MK; Jarius S; Kristoferitsch W; Berger T; Reindl M
    PLoS One; 2010 May; 5(5):e10455. PubMed ID: 20463974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.